Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anaplastic Lymphoma Kinase (ALK)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT04318938
What this trial is testing

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Who this might be right for
NSCLC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 118
Early research (Phase 1)Active Not RecruitingNCT02393625
What this trial is testing

Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

Who this might be right for
ALK-positive NSCLC
Novartis Pharmaceuticals 57
Not applicableUnknownNCT01637597
What this trial is testing

Crizotinib Efficacy In Non-Small Cell Lung Cancer Patients With Anaplastic Lymphoma Kinase Translocation

Who this might be right for
Non-small Cell Lung Cancer(NSCLC)
National Taiwan University Hospital 12
Testing effectiveness (Phase 2)Study completedNCT03779191
What this trial is testing

Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Who this might be right for
ALK Gene Rearrangement PositiveNon-Squamous Non-Small Cell Neoplasm of Lung
Instituto Nacional de Cancerologia de Mexico 41
Testing effectiveness (Phase 2)Active Not RecruitingNCT05015010
What this trial is testing

Alectinib in Neo-adjuvant Treatment of Stage III NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Gruppo Oncologico Italiano di Ricerca Clinica 33
Not applicableUnknownNCT01986595
What this trial is testing

A Pilot Study on ALK Gene Mutations in Neuroblastoma

Who this might be right for
Neuroblastoma
National Taiwan University Hospital 100
Testing effectiveness (Phase 2)Study completedNCT01801111
What this trial is testing

Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment

Who this might be right for
Non-Small-Cell Lung Carcinoma
Hoffmann-La Roche 138
Post-approval studies (Phase 4)Looking for participantsNCT05525338
What this trial is testing

Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels

Who this might be right for
Drug MonitoringCarcinoma, Non-Small-Cell LungLung Cancer+2 more
University Medical Center Groningen 196
Not applicableActive Not RecruitingNCT05370469
What this trial is testing

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies

Who this might be right for
Lung CancerEGFR Gene MutationEGFR+6 more
University of Virginia 30
Testing effectiveness (Phase 2)WithdrawnNCT03868423
What this trial is testing

Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers

Who this might be right for
Advanced Malignant NeoplasmALK Fusion Protein ExpressionALK Gene Amplification+8 more
Sameek Roychowdhury
Large-scale testing (Phase 3)Study completedNCT02604342
What this trial is testing

Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

Who this might be right for
Non-small Cell Lung Cancer
Hoffmann-La Roche 119
Early research (Phase 1)Ended earlyNCT04800822
What this trial is testing

PF-07284892 in Participants With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Pfizer 53
Early research (Phase 1)Active Not RecruitingNCT02321501
What this trial is testing

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

Who this might be right for
ALK PositiveLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+3 more
M.D. Anderson Cancer Center 37
Large-scale testing (Phase 3)Looking for participantsNCT06643416
What this trial is testing

Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia

Who this might be right for
ParonychiaEGFR-TKIALK-TKI
Queen Mary Hospital, Hong Kong 40
Not applicableStudy completedNCT02727335
What this trial is testing

Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements

Who this might be right for
Non-small Cell Lung CancerAnaplastic Lymphoma Kinase Gene Mutation
Intergroupe Francophone de Cancerologie Thoracique 318
Early research (Phase 1)Active Not RecruitingNCT03707938
What this trial is testing

Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Who this might be right for
Advanced Lung CarcinomaALK Gene RearrangementLung Non-Small Cell Carcinoma+4 more
M.D. Anderson Cancer Center 35
Not applicableNo Longer AvailableNCT02271139
What this trial is testing

Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

Who this might be right for
Non-Small Cell Lung Cancer
Genentech, Inc.
Not applicableActive Not RecruitingNCT04881916
What this trial is testing

Immune and Genomic Markers in ALK+ NSCLC

Who this might be right for
Anaplastic Lymphoma Kinase Gene TranslocationNon-Small Cell Lung Cancer
Massachusetts General Hospital 100
Early research (Phase 1)Study completedNCT01401504
What this trial is testing

Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors

Who this might be right for
Solid Tumor
Astellas Pharma Inc 29
Post-approval studies (Phase 4)WithdrawnNCT02487316
What this trial is testing

Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib

Who this might be right for
Systemic Anaplastic Large-Cell Lymphoma
Jun Zhu
Next Page